Telehealth Startups Market GLP-1 Drugs for Addiction Treatment

Telehealth is moving ahead of the evidence

Some telehealth companies are already offering GLP-1 drugs to people seeking help for substance use, despite the lack of an FDA decision on their use for addiction. The drugs show promise for treating addiction, particularly alcohol use disorder, but the evidence hasn’t yet led to an FDA ruling. That gap matters: a treatment can attract clinical interest before researchers and regulators have enough evidence to establish how well it works, for whom, and with what risks.

GLP-1 drugs are widely used for obesity, and interest in their potential effects on addictive behavior has opened a new area of research. The basic premise is that medicines affecting appetite and reward-related pathways might also influence cravings or consumption. That’s a reason to study the drugs, not proof that they treat addiction. Substance use disorders vary, and a result suggested in one context wouldn’t automatically apply to every substance or patient.

What an off-label prescription means

Startups Quel, Livelyhood, and Choose Your Horizon market off-label prescriptions of these widely used obesity drugs. Off-label prescribing means a clinician prescribes an approved medicine for a purpose that hasn’t received its own FDA approval. The practice can give clinicians flexibility, but it also leaves patients and providers without the same kind of indication-specific regulatory finding that would support a labeled use.

That distinction can be easy to miss in a telehealth setting. A company may describe a treatment as an option for substance use, while the underlying medicine’s approved use is for obesity. Marketing can make an early scientific hypothesis sound more settled than it is. The key question for patients is what evidence supports the particular use being offered, and how clearly the service explains the limits of that evidence.

Compounded products add another layer

Some of the companies also offer compounded versions that haven’t been approved by regulators. Compounding generally involves preparing a medication for an individual patient, but a compounded product isn’t the same as an FDA-approved drug product. That means the existence of an approved version of a medicine doesn’t itself establish that a compounded version has been reviewed or approved for safety, quality, or effectiveness.

This is the part most people overlook: there are two separate questions. One is whether GLP-1 drugs help with addiction; the other is whether a particular product and prescribing arrangement are appropriate for that patient. Combining those questions can make a service appear more established than the evidence warrants.

Why early promise isn’t a clinical answer

Early clinical interest can be a useful signal. It can point researchers toward a plausible mechanism and justify further study. But promise is not the same as demonstrated benefit. For a treatment to be established, evidence needs to clarify outcomes, side effects, dosing, and how the medicine fits alongside other forms of addiction care. Those answers can’t be assumed from a drug’s use for obesity.

The FDA’s lack of a decision on addiction use reflects that the use hasn’t reached a formal ruling; it doesn’t, by itself, resolve whether the research will ultimately support that use. Nor does the absence of a ruling mean every off-label prescription is ineffective. It means the distinction between preliminary evidence and an approved indication remains material.

Implications for patients and the field

For patients, the immediate challenge is separating a promising research direction from a proven treatment. If you're considering a telehealth service, ask what the prescription is intended to treat, whether it’s an approved or off-label use, and whether the product is compounded. A clear explanation should also acknowledge what’s still unknown. The numbers here are underwhelming in a different sense: the source describes promise, but offers no evidence of an FDA decision or settled clinical standard.

For the field, these services show how quickly commercial care can form around a scientific possibility. That can increase access to conversations with clinicians, but it can also put the burden of interpreting uncertain evidence on patients. Here's the thing: a company’s willingness to prescribe doesn’t answer the scientific question. That said, growing interest may encourage more study and clearer discussion of where these medicines could fit.

This is more significant than it looks because addiction treatment decisions affect people facing a serious health problem, and expectations can shape whether they seek or continue care. The evidence may develop, but for now the central point is simple: GLP-1 drugs show promise, particularly for alcohol use disorder, while their use for addiction remains without an FDA ruling. A possibility under study.